# Lisinopril

Drug · id `cardio:lisinopril` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Zestril

Browse, organ or system: Heart; Blood vessels  
Browse, condition area: High blood pressure; Coronary and vascular disease; Heart failure  

## In plain language

Lisinopril is an ACE inhibitor (angiotensin-converting enzyme inhibitor), a medicine taken by mouth. The US label read, for ZESTRIL tablets (lisinopril), lists three uses: treating high blood pressure in adults (and, for pediatric patients 6 years and older, in a separate statement), adding to other treatment of heart failure to reduce signs and symptoms of systolic heart failure, and reducing deaths when started within 24 hours of an acute myocardial infarction in people whose condition is stable. Zestril is the brand name on the label read.

## Technical summary

RxNorm ingredient 29046; UNII E7199S1YWR. The label describes the ingredient as lisinopril dihydrate, so UNII E7199S1YWR is the UNII of the dihydrate form and is a broad match. MeSH descriptor D017706 is Lisinopril. Class: Angiotensin Converting Enzyme Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Upsher-Smith Laboratories, LLC label for ZESTRIL (lisinopril) tablets, application NDA019777, effective 2025-01-02 in openFDA; Drugs@FDA lists the application's sponsor as TWI PHARMS. Other lisinopril labels, including the Qbrelis oral solution label, were not read. This page records label indications and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: Patients for whom the US label of lisinopril (Zestril) lists an indication: adult hypertension, systolic heart failure, acute myocardial infarction within 24 hours

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, pediatric patients 6 years and older); the heart failure and myocardial infarction indications do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for the other indications; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in adults (the same label sentence also names pediatric patients, recorded separately); as adjunct therapy for heart failure, to reduce signs and symptoms of systolic heart failure; and for the reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The hypertension indication names adults (and, separately, pediatric patients 6 years and older); the heart failure and myocardial infarction indications do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Adults for hypertension, as the passage read states; not stated for the other indications; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  2. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[2\], 1.2 Heart Failure. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  3. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[3\], 1.3 Reduction of Mortality in Acute Myocardial Infarction. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The label sentences that give the indications named in the statement, each quoted in the research quote table.
  4. Background: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: Effective date of the label text read, 20250102.
  5. Background: openFDA Drugs@FDA record for application NDA019777 (ZESTRIL, sponsor TWI PHARMS): product and sponsor (Regulator, edition The openFDA Drugs@FDA record for application NDA019777, returned on 2026-11-09. It lists the sponsor and the products of the application; only the first product listing is quoted.) <https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA019777%22&limit=1>
     Locator: results\[0\].products\[0\].brand\_name. Retrieved 2026-11-09T13:20:24Z. Source state: Current. Version fingerprint: 10404252bca5ef727ea05a4ea88c2e77deb09478b9d3791d6f5084684cf291f1.
     How it applies: Drugs@FDA product listing for application NDA019777, which confirms the product the label belongs to.

## Context: Children for whom the US label of lisinopril (Zestril) lists hypertension as an indication: pediatric patients 6 years of age and older

Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: pediatric patients 6 years of age and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of ZESTRIL (lisinopril) tablets, in the Upsher-Smith Laboratories, LLC version dated 2025-01-02 in openFDA, lists the medicine for the treatment of hypertension in pediatric patients 6 years of age and older.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Child; Population: Children with hypertension, as the indications section of the label describes them. The same label sentence also names adults, who are recorded in a separate context.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Label wording: pediatric patients 6 years of age and older; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for in children. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read, and the label has a boxed warning section whose content was not read or recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: The label sentence that names children in the hypertension indication, quoted in the research quote table.
  2. Background: openFDA drug label record for ZESTRIL (lisinopril tablets), Upsher-Smith Laboratories, LLC label: indications and class description (Regulator, edition The openFDA drug label record for set id 838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8 (manufacturer Upsher-Smith Laboratories, LLC, application NDA019777), returned on 2026-11-09. The label text is dated 2025-01-02 (effective\_time). Other openFDA records of labels for the same ingredient from other sponsors and repackagers exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22838c2d78-d2d8-4981-9ec9-e50ef9e1a5d8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:17:27Z. Source state: Current. Version fingerprint: 19d3c7aeb72318fb767e48d426a1cb5c0715b2f2de82e0028467c20b5e469335.
     How it applies: Effective date of the label text read, 20250102.

## Connected pages

- Lisinopril is an ACE inhibitor (FDA established pharmacologic class in RxClass): ACE inhibitors (`cardio:ace-inhibitors`)
- FDA label lists hypertension as an indication: Hypertension (high blood pressure) (`core:hypertension`) [a claim, not a settled fact; see claim `cardio:claim-fda-lisinopril-label-indications` and its context]
- FDA label lists adjunct therapy to reduce signs and symptoms of systolic heart failure as an indication: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-fda-lisinopril-label-indications` and its context]
- FDA label lists reduction of mortality in hemodynamically stable patients within 24 hours of acute myocardial infarction as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-lisinopril-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 5 registry products
- 6 registry trials

## Provenance

Content hash: 3232d527bcb89d64232242a9c0fe287af3d04c449800c2e32589cb38310a826d
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
